Open AccessFerumoxides–protamine sulfate is more effective than ferucarbotran for cell labeling: implications for clinically applicable cell tracking using MRI
Author(s) -
van Buul G. M.,
Farrell E.,
Kops N.,
van Tiel S. T.,
Bos P. K.,
Weinans H.,
Krestin G. P.,
van Osch G. J. V. M.,
Bernsen M. R.
Publication year - 2009
Publication title -
contrast media & molecular imaging
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.714
H-Index - 50
eISSN - 1555-4317
pISSN - 1555-4309
DOI - 10.1002/cmmi.289
Subject(s) - cell , stromal cell , protamine sulfate , intracellular , protamine , extracellular , chemistry , cancer research , medicine , biochemistry , heparin
The use of superparamagnetic iron oxide (SPIO) for labeling cells holds great promise for clinically applicable cell tracking using magnetic resonance imaging. For clinical application, an effectively and specifically labeled cell preparation is highly desired (i.e. a large amount of intracellular iron and a negligible amount of extracellular iron). In this study we performed a direct comparison of two SPIO labeling strategies that have both been reported as efficient and clinically translatable approaches. These approaches are cell labeling using ferumoxides–protamine complexes or ferucarabotran particles. Cell labeling was performed on primary human bone marrow stromal cells (hBMSCs) and chondrocytes. For both cell types ferumoxides–protamine resulted in a higher percentage of labeled cells, a higher total iron load, a larger amount of intracellular iron and a lower amount of extracellular iron aggregates, compared with ferucarbotran. Consequently, hBMSC and chondrocyte labeling with ferumoxides–protamine is more effective and results in more specific cell labeling than ferucarbotran. Copyright © 2009 John Wiley & Sons, Ltd.